Comparison · NCT02096354-b4217c2a
RRx-001 Followed by Irinotecan vs Regorafenib Followed by Irinotecan: Clinical Benefit Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RRx-001 Followed by Irinotecan vs Regorafenib Followed by Irinotecan: Clinical Benefit Rate. Trial comparisons, record NCT02096354-b4217c2a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02096354-b4217c2a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.708 | 0.508 | 0.851 | wilson | |
| Risk in group 2 | 0.4 | 0.168 | 0.687 | wilson | |
| Risk difference, group 1 minus group 2 | 0.308 | -0.0418 | 0.58 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.77 | 0.795 | 3.95 | log | |
| Odds ratio, group 1 over group 2 | 3.64 | 0.78 | 17 | log | |
| Number needed to treat, for one more participant with the outcome on RRx-001 Followed by Irinotecan than on Regorafenib Followed by Irinotecan | 3.24 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RRx-001 Followed by Irinotecan | Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab) | 17 | 24 | OG000 |
| Group 2 | Regorafenib Followed by Irinotecan | Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab) | 4 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Clinical Benefit Rate
- Description
The period from study entry through Disease Control. Disease Control Rate (DCR) also correlates to Clinical Benefit Rate (CBR), defined as the percentage of subjects with CR, PR or SD relative to the total number of treated subjects
- Time frame
- Up to 2 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- NCT number
- NCT02096354
- Phases
- PHASE2
- Conditions
- Colorectal Neoplasms
- Interventions
- RRx-001, Regorafenib, Irinotecan
- Lead sponsor
- EpicentRx, Inc.
- Results first posted
- 2024-10-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02096354?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02096354-b4217c2a